Trinity Capital Inc. Provides $35 Million in Growth Capital to Neuros Medical, Inc. to Scale Pain Management Therapy Adoption

Rhea-AI Summary

Trinity Capital (Nasdaq: TRIN) committed $35 million in growth capital to Neuros Medical on March 10, 2026 to scale commercialization of the FDA-approved Altius Direct Electrical Nerve Stimulation System.

The funding is intended to expand market access for a non-opioid neuromodulation therapy for post-amputation phantom and residual limb pain and provide additional financial flexibility under Neuros Medical's debt facility.

Positive

• Growth capital of $35 million committed by Trinity Capital
• Supports commercialization scale-up for FDA-approved Altius system
• Provides additional financial flexibility via an expanded debt facility

Negative

• Capital is debt facility expansion, which may increase leverage for Neuros Medical

News Market Reaction – TRIN

+0.20%

+0.20% Session close to close

In the Mar 10 session, TRIN gained 0.20%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlighted Trinity Capital’s continued portfolio expansion through a $35M growth ...

Analysis

This announcement highlighted Trinity Capital’s continued portfolio expansion through a $35M growth capital commitment to Neuros Medical, supporting commercialization of an FDA-approved neuromodulation therapy for post-amputation pain. It followed record 2025 financial results and other recent growth financings, indicating sustained deployment activity. Investors may track how this and similar deals affect overall asset quality, diversification, and income generation relative to prior commitments to Dwelly and Motorway, as well as any updates to credit ratings and non-accrual levels.

Key Figures

Growth capital commitment: $35 million

1 metrics

Growth capital commitment $35 million Debt facility provided by Trinity Capital to Neuros Medical

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 26	Growth capital deal	Positive	-1.3%	$50M growth capital commitment to Dwelly to scale UK marketplace.
Feb 25	Earnings results	Positive	+2.5%	Record 2025 investment income, net investment income, NAV, and AUM growth.
Feb 03	Prelim earnings	Positive	+0.5%	Preliminary Q4 2025 NII and NAV estimates with low non‑accrual levels.
Feb 02	Growth capital deal	Positive	-2.9%	£25M growth capital facility for Motorway to support UK expansion.
Jan 28	Credit rating	Positive	+0.5%	Morningstar DBRS confirmed BBB (low) rating, trend revised to Positive.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive portfolio and rating news has produced mixed reactions, with some capital deployment announcements followed by modest sell-offs while earnings and rating updates have generally aligned with positive price moves.

Recent Company History

Over the last few months, Trinity Capital reported record 2025 results, with total investment income of $293.7M and net investment income of $144.1M, alongside NAV per share rising to $13.42. It has been actively deploying growth capital, including $50M to Dwelly and £25M to Motorway, and received a BBB (low) rating with a trend revised to Positive. Today’s $35M commitment to Neuros Medical continues this pattern of portfolio growth via specialized lending.

Key Terms

neuromodulation, peripheral nerve, phantom limb, fda-approved, +2 more

6 terms

neuromodulation medical

"a MedTech company focused on alleviating chronic post-amputation pain and restoring quality of life through neuromodulation technologies."

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

peripheral nerve medical

"targets pain at its source by interrupting peripheral nerve signals responsible for phantom limb and residual limb pain."

Peripheral nerves are the bundles of fibers that carry signals between the brain and spinal cord and the rest of the body, controlling movement, touch, pain and automatic functions like heartbeat and digestion. Think of them as electrical wiring that links a central computer to appliances in a house. For investors, conditions or treatments affecting these nerves influence demand for drugs, devices and diagnostics, clinical trial risk and regulatory review, and therefore company revenue and valuation.

phantom limb medical

"peripheral nerve signals responsible for phantom limb and residual limb pain."

An experience in which a person feels sensations, including pain, coming from a limb or body part that has been amputated or is otherwise missing; the brain continues to send signals or interpret signals as if the limb were still there, similar to a housekeeper mistaking an empty room for one that still contains furniture. Investors care because phantom limb pain and related sensations drive demand for medical devices, drugs, therapies and rehabilitation services, shape clinical trial needs and regulatory reviews, and influence potential market size and reimbursement decisions in healthcare and biotech.

fda-approved regulatory

"Neuros Medical's FDA-approved Altius Direct Electrical Nerve Stimulation System targets pain at its source"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

direct electrical nerve stimulation medical

"Altius Direct Electrical Nerve Stimulation System targets pain at its source"

Direct electrical nerve stimulation is the delivery of small, controlled electrical pulses straight to a nerve using electrodes placed on the skin or implanted near the nerve, with the goal of changing how that nerve signals the body. For investors, it matters because it is the core mechanism behind a growing class of medical devices and treatments that can replace or supplement drugs for chronic conditions, affecting device sales, regulatory approval paths, and potential market size much like a new engine design reshapes an entire car market.

debt facility financial

"This expansion of our debt facility provides important financial flexibility as Neuros enters the next phase"

A debt facility is a formal arrangement that lets a company borrow money from a bank or group of lenders under agreed terms, such as a one-time loan, a revolving credit line, or other financed options—think of it as a business’s mortgage or credit card with set rules. Investors care because it affects how much cash a company has for operations and growth, how much interest and risk it carries, and whether loan terms could limit dividends, share buybacks, or trigger default if financial targets aren’t met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHOENIX, March 10, 2026 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading international alternative asset manager, today announced the commitment of $35 million in growth capital to Neuros Medical, Inc., a MedTech company focused on alleviating chronic post-amputation pain and restoring quality of life through neuromodulation technologies.

Neuros Medical's FDA-approved Altius Direct Electrical Nerve Stimulation System targets pain at its source by interrupting peripheral nerve signals responsible for phantom limb and residual limb pain. The system enables patients to activate therapy when needed, delivering targeted pain relief without relying on continuous medication. With treatment options historically limited to opioid-based therapies, Altius offers a differentiated alternative for post-amputation pain.

"Neuros Medical has reached an important inflection point as their technology moves into real-world adoption. We are proud to continue to support their team as they expand access to a differentiated therapy that addresses a significant need within the life sciences ecosystem," said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital.

This new capital will help Neuros Medical scale the commercialization of the Altius system and expand into new markets.

"We appreciate the continued partnership from Trinity," said David Veino, President & CEO of Neuros Medical. "The Trinity team has been an important partner prior to us achieving FDA approval and will remain an important partner as we expand. This expansion of our debt facility provides important financial flexibility as Neuros enters the next phase of its mission to Relieve Pain and Restore Life for this underserved patient population."

About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $5.5 billion across over 463 investments since inception in 2008 (as of December 31, 2025). Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and Europe. For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn and X (@trincapital).

About Neuros Medical, Inc.
There are over two million patients in the U.S. living with limb loss and approximately 300,000 new lower limb amputations occurring every year. Post-amputation pain includes both phantom limb pain and residual limb pain, and impacts up to 80% of amputees, representing a significant unmet medical need, as existing treatment options are limited and consist primarily of opioids and gabapentinoids. Neuros Medical is a privately held company and the maker of the Altius® Direct Electrical Nerve Stimulation System, which is FDA-approved and is indicated as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees. Our mission is to relieve pain and restore life for people suffering with post-amputation pain. We are a passionate team guided by our core values and committed to our patients and the healthcare professionals who care for them.

View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-35-million-in-growth-capital-to-neuros-medical-inc-to-scale-pain-management-therapy-adoption-302708560.html

SOURCE Trinity Capital Inc.

FAQ

What did Trinity Capital (TRIN) announce on March 10, 2026 regarding Neuros Medical?

Trinity Capital committed $35 million in growth capital to Neuros Medical to scale commercialization. According to the company, the funding expands access to the FDA-approved Altius system and provides financial flexibility through an expanded debt facility.

How will the $35 million from TRIN affect Neuros Medical's commercialization of Altius?

The capital is intended to help scale commercialization and expand into new markets. According to the company, the funding supports market expansion, broader patient access, and operational steps needed for real-world adoption of Altius.

What is the Altius system and why is Trinity Capital funding it?

Altius is an FDA-approved direct electrical nerve stimulation system for post-amputation pain. According to the company, Altius offers targeted, on-demand neuromodulation as a non-opioid alternative for phantom and residual limb pain, prompting Trinity's investment.

Does the Trinity Capital investment change Neuros Medical's financial structure?

The announcement expands Neuros Medical's debt facility, increasing financial flexibility but adding leverage. According to the company, the expanded facility is intended to support commercialization while providing balance sheet flexibility.

What impact might the TRIN-backed funding have for shareholders of Trinity Capital (TRIN)?

The investment represents a growth-capital deployment into life sciences commercialization efforts. According to the company, the deal targets market expansion of an FDA-approved therapy, which could influence portfolio returns depending on commercial outcomes and credit performance.